Poeciguamerin
Antistasin-domain dual analgesic + antithrombotic serine protease inhibitor from Poecilobdella manillensis — Wang 2023 explains the painless-bleed phenotype.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Antistasin-domain dual analgesic + antithrombotic serine protease inhibitor from Poecilobdella manillensis — Wang 2023 explains the painless-bleed phenotype.
- Evidence level
- Preclinical (animal)
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
Poeciguamerin's preclinical analgesic + antithrombotic activity in murine models does NOT establish clinical efficacy in humans. No FDA-approved derivative exists; P. manillensis is not the FDA-cleared K040187 medicinal leech species.
Molecular Profile
- Category
- Proteinase Inhibitor
- Evidence tier
- Preclinical
- Molecular weight
- 5,500 Da
- Source species
- Poecilobdella manillensis
- Discovered
- 2023 · Wang C et al.
Biological Targets
- → leukocyte elastase (primary)
- → FXIIa
- → kallikrein
Key Citations
- Wang C et al. (2023), Int J Mol Sci · PMID 37446275
External Resources
Related Proteinase Inhibitor Compounds
Hirustasin
Serine proteinase inhibitor targeting tissue kallikrein — anti-inflammatory pathway.
Eglin C
Potent inhibitor of human leukocyte elastase and cathepsin G — anti-inflammatory protein widely used as research tool.
Bdellin B3
Kazal-type proteinase inhibitor targeting trypsin and plasmin — modulates inflammatory cascade.
LDTI (Leech-Derived Tryptase Inhibitor)
Selective inhibitor of human mast cell tryptase — anti-inflammatory pathway.